Roland Griffiths PhD

Professor of Behavioral Biology




Johnson, M.W., Hendricks, P.S., Barrett, F.S., & Griffiths, R.R. (2019). Classic psychedelics: An integrative review of epidemiology, mystical experience, brain network function, and therapeutics. Pharmacology & Therapeutics, 197, 83-102.

Sweeney, M.M., Meredith, S.E., Juliano, L.M., Evatt, D.P. & Griffiths, R.R. (2019). A randomized controlled trial of a manual-only treatment for reduction and cessation of problematic caffeine use. Drug and Alcohol Dependence, 195, 45-51. 

Garcia-Romeu, A., Davis, A.K., Erowid, F., Erowid, E., Griffiths, R.R., & Johnson, M.W. (in press). Cessation and reduction in alcohol consumption and misuse after psychedelic use. Journal of Psychopharmacology.

Barrett, F.S., Carbonaro, T.M., Hurwitz, E., Johnson, M.W., & Griffiths, R.R. (2018). Double-blind comparison of the two hallucinogens psilocybin and dextromethorphan: Effects on cognition. Psychopharmacology, 235, 2915-2927.

Johnson, M.W., Griffiths, R.R., Hendricks, P.S., & Henningfield, J.E. (2018). The abuse potential of medical psilocybin according to the 8 factors of the Controlled Substances Act. Neuropharmacology, 142, 143-166.

Sweeney, M. M., Juliano, L. M., Ferré, S., Griffiths, R. R. (2018). The Pharmacology of Caffeine. In Miller, S. C., Fiellin, D. A., Rosenthal, R. N., Saitz, R., (Eds.) The American Society of Addiction Medicine Principles of Addiction Medicine, Sixth Edition. Philadelphia: Wolters Kluwer.

Carbonaro, T.M., Johnson, M.W., Hurwitz, E., & Griffiths, R.R. (2018). Double-blind comparison of the two hallucinogens psilocybin and dextromethorphan: similarities and differences in subjective experiences. Psychopharmacology, 235, 521-534. 

Griffiths, R.R., Johnson, M.W., Richards, W.A., Richards B.D., Jesse, R., MacLean, K.A., Barrett, F.S., Cosimano, M.P., & Klinedinst, K.A. (2018). Psilocybin-occasioned mystical-type experience in combination with
meditation and other spiritual practices produces enduring positive changes in psychological functioning and in trait measures of prosocial attitudes and behaviors. Journal of Psychopharmacology, 32(1), 49-69. 

Barrett, F.S., Robbins, H., Smooke, D., Brown,J.L., Griffiths, R.R. (2017). Qualitative and quantitative features of music reported to support peak mystical experiences during psychedelic therapy sessions. Frontiers in Psychology, July 2017, 8, Article 1238.

Barrett F.S., & Griffiths R.R. (2017). Classic hallucinogens and mystical experiences: Phenomenology and neural correlates, Curr Topics Behav Neuroscience, 36, 393-430.

Sweeney, M.M., Meredith, S.E., Evatt, D.P, & Griffiths, R.R. (2017). Effects of caffeine on alcohol reinforcement: Beverage choice, self-administration, and subjective ratings. Psychopharmacology, 234(5), 877-888.

Griffiths R.R., Johnson, M.W., Carducci, M.A., Umbricht, A. Richards, W.A., Richards, B.D., Cosimano, M.P., Klinedinst, M.A. (2016). Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: A randomized double-blind trial. Journal of Psychopharmacology, 30(12), 1181-1197.

Maqueda, A.E., Valle, M., Addy, P.H., Antonijoan, R.M., Puntes, M., Coimbra, J., Ballester, M.R., Garrido, M., González, M., Claramunt, J., Barker, S., Lomnicka, I., Waguespack, M., Johnson, M.W., Griffiths, R.R., & Riba, J. (2016). Naltrexone but not ketanserin antagonizes the subjective, cardiovascular, and neuroendocrine effects of salvinorin-A in humans. International Journal of Neuropsychopharmacology, 19(7), 1-13.

Johnson, M.W., MacLean, K.A., Caspers, M.J., Prisinzano, Griffiths, R.R. (2016). Time course of pharmacokinetic and hormonal effects of inhaled high-dose salvinorin A in humans. Journal of Psychopharmacology, 30(4), 323-329.

Maqueda, A.E., Valle, M., Addy, P.H., Antonijoan, R.M., Puntes, M., Coimbra, J., Ballester, M.R., Garrido, M., González, M., Claramunt, J., Barker, S., Johnson, M.W., Griffiths, R.R., & Riba, J. (2015). Salvinorin-A induces intense dissociative effects, blocking external sensory perception and modulating interoception and sense of body ownership in humans. International Journal of Neuropsychopharmacology. 18(12) 1-14.

Johnson, M.W., Garcia-Romeu, A., Cosimano, M.P., & Griffiths, R.R. (2014). Pilot study of the 5-HT2AR agonist psilocybin in the treatment of tobacco addiction. Journal of Psychopharmacology, 11, 983-992.

Caspers, M.J., Williams, T.D., Lovell, K.M. Lozama, A, Butelman, E.R., Kreek, M.J., Johnson, M. Griffiths, R., MacLean, K., & Prisinzano, T.E. (2013). LC-MS/MS quantification of salvinorin A from biological fluids. Analytical Methods 5, 7042-7048.

MacLean, K.A., Johnson, M.W., Reissig, C.J., Prisinzano, T.E., & Griffiths, R.R. (2013). Dose-related effects of salvinorin A in humans: Dissociative, hallucinogenic and memory effects. Psychopharmacology, 226, 381-392.

Carter, L.P., Kleykamp, B.A., Griffiths, R.R., & Mintzer, M.Z. (2013). Cognitive effects of intramuscular ketamine and oral triazolam in healthy volunteers. Psychopharmacology, 226, 53-63.